Am J Psychiatry 1987; 144:468-471
Copyright © 1987 by American Psychiatric Association
Induction of depression with oxotremorine in patients with Alzheimer's disease
KL Davis, E Hollander, M Davidson, BM Davis, RC Mohs and TB Horvath
Cholinergic neurotransmission has long been implicated in the development
of depression. In this study seven patients with Alzheimer's disease were
given oral oxotremorine, a long-acting cholinergic agonist, to assess the
drug's effects on cognitive function. There were unexpected depressive
reactions in five of the seven patients; three patients dropped out of the
study because of the side effects. Cardiovascular effects of the drug were
negligible, but its effect on memory and cognition remains unknown because
of the small number of subjects who completed the study.
This article has been cited by other articles:
|
|
|
|
 
M. S. Mega, I. D. Dinov, L. Lee, S. M. O'Connor, D. M. Masterman, B. Wilen, F. Mishkin, A. W. Toga, and J. L. Cummings
Orbital and Dorsolateral Frontal Perfusion Defect Associated With Behavioral Response to Cholinesterase Inhibitor Therapy in Alzheimer's Disease
J Neuropsychiatry Clin Neurosci,
May 1, 2000;
12(2):
209 - 218.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. J. Thal, M. Forrest, H. Loft, and H. Mengel
Lu 25-109, a muscarinic agonist, fails to improve cognition in Alzheimer's disease
Neurology,
January 25, 2000;
54(2):
421 - 421.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. L. Cummings
Cholinesterase Inhibitors: A New Class of Psychotropic Compounds
Am J Psychiatry,
January 1, 2000;
157(1):
4 - 15.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
R. D. Schwarz, M. J. Callahan, L. L. Coughenour, M. R. Dickerson, J. J. Kinsora, W. J. Lipinski, C. A. Raby, C. J. Spencer, and H. Tecle
Milameline (CI-979/RU35926): A Muscarinic Receptor Agonist with Cognition-Activating Properties: Biochemical and In Vivo Characterization
J. Pharmacol. Exp. Ther.,
November 1, 1999;
291(2):
812 - 822.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
J. L. Cummings and C. Back
The Cholinergic Hypothesis of Neuropsychiatric Symptoms in Alzheimer's Disease
Am J Geriatr Psychiatry,
May 1, 1998;
6(2):
64S - 78.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
N.H.P. Allen and A. Burns
The treatment of Alzheimer's disease
J Psychopharmacol,
January 1, 1995;
9(1):
43 - 56.
[PDF]
|
|
|
|
|
|
|
A. J. Flint
Delusions, hallucinations and depression in Alzheimer's disease: A biological perspective
American Journal of Alzheimer's Disease and Other Dementias,
May 1, 1991;
6(3):
21 - 28.
[Abstract]
[PDF]
|
|
|
|
|
|
|
A. Sahgal, A.B. Keith, and S. Lloyd
Effects of nicotine, oxotremorine and 9-amino 1,2,3,4- tetrahydroacridine (tacrine) on matching and non matching to position in rats: no evidence for mnemonic enhancement
J Psychopharmacol,
January 1, 1990;
4(4):
210 - 218.
[Abstract]
[PDF]
|
|
|
Get information about faster international access.
Privacy Policy
Copyright © 1987
American Psychiatric Association.
All rights reserved.
Home
| Search
| Current Issue
| Past Issues
| Subscribe
| All APPI Journals
| Help
| Contact Us
|
